FIC20200022I1 - Yhdistelmä, joka käsittää fosnetupitanttia tai sen farmaseuttisesti hyväksyttävää suolaa ja palonosetronia tai sen farmaseuttisesti hyväksyttävää suolaa - Google Patents

Yhdistelmä, joka käsittää fosnetupitanttia tai sen farmaseuttisesti hyväksyttävää suolaa ja palonosetronia tai sen farmaseuttisesti hyväksyttävää suolaa

Info

Publication number: FIC20200022I1
Authority: FI; Finland
Prior art keywords: pharmaceutically acceptable; acceptable salt; fosnetupitant; palonosetron; combination
Prior art date: 2011-11-29

Application number

FIC20200022C

Other languages

English (en)

Original Assignee

Helsinn Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-29

Filing date

2020-06-24

Publication date

2020-06-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48094815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FIC20200022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-06-24 Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa

2020-06-24 Publication of FIC20200022I1 publication Critical patent/FIC20200022I1/fi

Links

150000003839 salts Chemical class 0.000 title 2
HZIYEEMJNBKMJH-UHFFFAOYSA-N [4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl]methyl hydrogen phosphate Chemical compound C=1N=C(N2CC[N+](C)(COP(O)([O-])=O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HZIYEEMJNBKMJH-UHFFFAOYSA-N 0.000 title 1
229950010727 fosnetupitant Drugs 0.000 title 1
CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 title 1
229960002131 palonosetron Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/025—Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

FIC20200022C 2011-11-29 2020-06-24 Yhdistelmä, joka käsittää fosnetupitanttia tai sen farmaseuttisesti hyväksyttävää suolaa ja palonosetronia tai sen farmaseuttisesti hyväksyttävää suolaa FIC20200022I1 (fi)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161564537P	2011-11-29	2011-11-29
US13/478,361 US8426450B1 (en)	2011-11-29	2012-05-23	Substituted 4-phenyl pyridines having anti-emetic effect
PCT/US2012/066778 WO2013082102A1 (en)	2011-11-29	2012-11-28	Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases

Publications (1)

Publication Number	Publication Date
FIC20200022I1 true FIC20200022I1 (fi)	2020-06-24

Family

ID=48094815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FIC20200022C FIC20200022I1 (fi)	2011-11-29	2020-06-24	Yhdistelmä, joka käsittää fosnetupitanttia tai sen farmaseuttisesti hyväksyttävää suolaa ja palonosetronia tai sen farmaseuttisesti hyväksyttävää suolaa

Country Status (50)

Country	Link
US (7)	US8426450B1 (fi)
EP (1)	EP2785706B1 (fi)
JP (3)	JP5635708B2 (fi)
KR (1)	KR101979050B1 (fi)
CN (6)	CN112979543B (fi)
AP (1)	AP2014007729A0 (fi)
AR (1)	AR089019A1 (fi)
AU (1)	AU2012346133B2 (fi)
BR (1)	BR112014012878B1 (fi)
CA (1)	CA2850644C (fi)
CL (1)	CL2014001280A1 (fi)
CO (1)	CO6990728A2 (fi)
CR (1)	CR20140312A (fi)
CY (2)	CY1118416T1 (fi)
DK (1)	DK2785706T3 (fi)
DO (1)	DOP2014000115A (fi)
EA (1)	EA026553B1 (fi)
EC (1)	ECSP14003642A (fi)
ES (1)	ES2603958T3 (fi)
FI (1)	FIC20200022I1 (fi)
FR (1)	FR20C1029I2 (fi)
GE (1)	GEP201706695B (fi)
GT (1)	GT201400102A (fi)
HR (1)	HRP20161708T1 (fi)
HU (2)	HUE032288T2 (fi)
IL (1)	IL232859B (fi)
IN (1)	IN2014CN04907A (fi)
JO (1)	JO3202B1 (fi)
LT (2)	LT2785706T (fi)
MA (1)	MA35836B1 (fi)
MD (1)	MD4539C1 (fi)
ME (1)	ME02561B (fi)
MX (1)	MX2014006423A (fi)
MY (1)	MY165514A (fi)
NI (1)	NI201400043A (fi)
NL (1)	NL301047I2 (fi)
PE (1)	PE20141421A1 (fi)
PH (1)	PH12014501199B1 (fi)
PL (1)	PL2785706T3 (fi)
PT (1)	PT2785706T (fi)
RS (1)	RS55448B1 (fi)
SG (1)	SG11201402044XA (fi)
SI (1)	SI2785706T1 (fi)
SM (2)	SMT201600467T1 (fi)
TN (1)	TN2014000165A1 (fi)
TW (1)	TWI638806B (fi)
UA (1)	UA115136C2 (fi)
UY (1)	UY34472A (fi)
WO (1)	WO2013082102A1 (fi)
ZA (1)	ZA201404787B (fi)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10449177B2 (en)	2010-08-19	2019-10-22	Buck Institute For Research On Aging	Methods of treating mild cognitive impairment (MCI) and related disorders
CN103260924B (zh)	2010-12-07	2016-11-09	艾里逊变速箱公司	用于混合动力电动车的能量存储系统
US9273043B2 (en)	2011-06-22	2016-03-01	Purdue Pharma L.P.	TRPV1 antagonists including dihydroxy substituent and uses thereof
US8426450B1 (en)	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
CN105745198B (zh)	2013-11-08	2018-09-21	橘生药品工业株式会社	羧甲基哌啶衍生物
EP3140007A1 (en) *	2014-05-05	2017-03-15	Apicore US LLC	Methods of making netupitant and intermediates thereof
TWI649307B (zh)	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
TW201613888A (en) *	2014-09-26	2016-04-16	Helsinn Healthcare Sa	Crystalline forms of an NK-1 antagonist
UA125245C2 (uk)	2014-10-06	2022-02-09	Вертекс Фармасьютикалз Інкорпорейтед	Модулятори регулятора трансмембранної провідності при муковісцидозі
CN105061303A (zh) *	2015-08-03	2015-11-18	成都欣捷高新技术开发有限公司	一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
US10005803B2 (en)	2015-10-06	2018-06-26	Helsinn Healthcare Sa	Crystalline forms of fosnetupitant
CN106892864A (zh) *	2015-12-21	2017-06-27	上海科胜药物研发有限公司	一种奈妥皮坦游离碱的晶型a及其制备方法
WO2017173274A1 (en)	2016-03-31	2017-10-05	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA3025837C (en) *	2016-06-06	2024-02-13	Helsinn Healthcare Sa	Physiologically balanced injectable formulations of fosnetupitant
RS62670B1 (sr)	2016-09-30	2021-12-31	Vertex Pharma	Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora
MD3551622T2 (ro)	2016-12-09	2021-03-31	Vertex Pharma	Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
CN108619525B (zh) *	2017-03-15	2020-12-29	和龙	奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途
EP3634402A1 (en)	2017-06-08	2020-04-15	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3104811C (en)	2017-06-30	2024-05-28	Chase Therapeutics Corporation	Composition comprising pramipexole and nk1-antagonists for treating depression
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	METHODS OF TREATING CYSTIC FIBROSIS
CA3071278A1 (en)	2017-08-02	2019-02-07	Vertex Pharmaceuticals Incorporated	Processes for preparing pyrrolidine compounds
CN107698500A (zh) *	2017-10-17	2018-02-16	扬子江药业集团四川海蓉药业有限公司	一种奈妥匹坦的制备方法
EP3697774A1 (en)	2017-10-19	2020-08-26	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of cftr modulators
JP7245834B2 (ja)	2017-12-08	2023-03-24	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
WO2019138162A1 (en) *	2018-01-12	2019-07-18	Orion Corporation	Palonosetron for the treatment or prevention of nausea and vomiting
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7156154B2 (ja) *	2019-04-18	2022-10-19	株式会社島津製作所	培地処理システム及び培地処理方法
CN112174881B (zh) *	2019-07-04	2022-06-21	上海森辉医药有限公司	一种奈妥匹坦的衍生物及其制备方法
CN112778370A (zh) *	2019-11-06	2021-05-11	扬子江药业集团江苏海慈生物药业有限公司	一种制备福奈妥匹坦的方法
BR112022018876A2 (pt)	2020-04-03	2022-11-22	Nerre Therapeutics Ltd	Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
EP4157270A1 (en) *	2020-06-02	2023-04-05	NeRRe Therapeutics Limited	Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US12097197B2 (en)	2021-12-21	2024-09-24	Slayback Pharma Llc	Stable liquid compositions of netupitant and palonosetron
WO2025036703A1 (en)	2023-08-13	2025-02-20	Helsinn Healthcare Sa	Fosnetupitant for administration via intravenous bolus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE261730T1 (de)	1997-12-31	2004-04-15	Univ Kansas	Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
DE60045564D1 (de) *	1999-02-24	2011-03-03	Hoffmann La Roche	4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
US6303790B1 (en)	1999-11-29	2001-10-16	Hoffman-La Roche Inc.	Process for the preparation of pyridine derivatives
DK1103545T3 (da) *	1999-11-29	2004-03-15	Hoffmann La Roche	2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6362172B2 (en) *	2000-01-20	2002-03-26	Bristol-Myers Squibb Company	Water soluble prodrugs of azole compounds
US8933236B2 (en)	2012-05-22	2015-01-13	Xenon Pharmaceuticals Inc.	N-substituted benzamides and methods of use thereof
EP1303490B1 (en)	2000-07-14	2008-07-09	F. Hoffmann-La Roche Ag	N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) *	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
DE60123661T2 (de)	2000-12-14	2007-08-16	F. Hoffmann-La Roche Ag	Selbstemulgierende lipidmatrix (selm)
US6531597B2 (en)	2001-02-13	2003-03-11	Hoffmann-La Roche Inc.	Process for preparation of 2-phenyl acetic acid derivatives
US7745625B2 (en) *	2004-03-15	2010-06-29	Bristol-Myers Squibb Company	Prodrugs of piperazine and substituted piperidine antiviral agents
US20060030600A1 (en) *	2004-08-06	2006-02-09	Patrick Schnider	Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CN101146775B (zh) *	2005-03-23	2012-07-18	弗·哈夫曼-拉罗切有限公司	用于呕吐的用作nk-i拮抗剂的代谢物
CN101282979B (zh) *	2005-09-13	2011-09-21	卫材R&D管理有限公司	稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法
GB0808747D0 (en)	2008-05-14	2008-06-18	Glaxo Wellcome Mfg Pte Ltd	Novel compounds
UA108077C2 (xx) *	2009-07-02	2015-03-25		Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
MX2012005347A (es) *	2009-11-18	2012-08-03	Helsinn Healthcare Sa	Composiciones para tratar nausea y vomito centralmente mediados.
ES2647361T3 (es) *	2010-01-07	2017-12-21	Alkermes Pharma Ireland Limited	Profármacos de sales de amonio cuaternario
US8609637B2 (en) *	2010-12-02	2013-12-17	The University Of Kansas	Prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-(1H)-one and derivatives thereof
US9403772B2 (en)	2011-11-29	2016-08-02	Helsinn Healthcare Sa	4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en)	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect

2012
- 2012-05-23 US US13/478,361 patent/US8426450B1/en active Active
- 2012-11-19 JO JOP/2012/0348A patent/JO3202B1/ar active
- 2012-11-28 PE PE2014000630A patent/PE20141421A1/es active IP Right Grant
- 2012-11-28 CN CN202110222556.5A patent/CN112979543B/zh active Active
- 2012-11-28 PL PL12798549T patent/PL2785706T3/pl unknown
- 2012-11-28 KR KR1020147017431A patent/KR101979050B1/ko active Active
- 2012-11-28 RS RS20161103A patent/RS55448B1/sr unknown
- 2012-11-28 HR HRP20161708TT patent/HRP20161708T1/hr unknown
- 2012-11-28 CA CA2850644A patent/CA2850644C/en active Active
- 2012-11-28 BR BR112014012878-2A patent/BR112014012878B1/pt active IP Right Grant
- 2012-11-28 CN CN201710324776.2A patent/CN106986822B/zh active Active
- 2012-11-28 SI SI201230810A patent/SI2785706T1/sl unknown
- 2012-11-28 ES ES12798549.7T patent/ES2603958T3/es active Active
- 2012-11-28 DK DK12798549.7T patent/DK2785706T3/en active
- 2012-11-28 IN IN4907CHN2014 patent/IN2014CN04907A/en unknown
- 2012-11-28 PT PT127985497T patent/PT2785706T/pt unknown
- 2012-11-28 MX MX2014006423A patent/MX2014006423A/es unknown
- 2012-11-28 WO PCT/US2012/066778 patent/WO2013082102A1/en active Application Filing
- 2012-11-28 HU HUE12798549A patent/HUE032288T2/hu unknown
- 2012-11-28 SG SG11201402044XA patent/SG11201402044XA/en unknown
- 2012-11-28 UA UAA201407175A patent/UA115136C2/uk unknown
- 2012-11-28 CN CN201280058800.8A patent/CN104053652A/zh active Pending
- 2012-11-28 CN CN202010607408.0A patent/CN111662330B/zh active Active
- 2012-11-28 CN CN202110222524.5A patent/CN112961104A/zh active Pending
- 2012-11-28 AU AU2012346133A patent/AU2012346133B2/en active Active
- 2012-11-28 GE GEAP201213508A patent/GEP201706695B/en unknown
- 2012-11-28 EA EA201400624A patent/EA026553B1/ru unknown
- 2012-11-28 MD MDA20140059A patent/MD4539C1/ro active IP Right Grant
- 2012-11-28 JP JP2013555647A patent/JP5635708B2/ja active Active
- 2012-11-28 CN CN201610957278.7A patent/CN106518924B/zh active Active
- 2012-11-28 UY UY0001034472A patent/UY34472A/es active IP Right Grant
- 2012-11-28 MY MYPI2014001505A patent/MY165514A/en unknown
- 2012-11-28 LT LTEP12798549.7T patent/LT2785706T/lt unknown
- 2012-11-28 EP EP12798549.7A patent/EP2785706B1/en active Active
- 2012-11-28 SM SM20160467T patent/SMT201600467T1/it unknown
- 2012-11-28 ME MEP-2016-283A patent/ME02561B/me unknown
- 2012-11-28 AP AP2014007729A patent/AP2014007729A0/xx unknown
- 2012-11-29 AR ARP120104473A patent/AR089019A1/es active IP Right Grant
- 2012-11-29 TW TW101144681A patent/TWI638806B/zh active
2013
- 2013-04-17 US US13/864,381 patent/US8895586B2/en active Active
2014
- 2014-04-18 TN TNP2014000165A patent/TN2014000165A1/en unknown
- 2014-05-13 NI NI201400043A patent/NI201400043A/es unknown
- 2014-05-15 CL CL2014001280A patent/CL2014001280A1/es unknown
- 2014-05-26 GT GT201400102A patent/GT201400102A/es unknown
- 2014-05-28 PH PH12014501199A patent/PH12014501199B1/en unknown
- 2014-05-28 IL IL232859A patent/IL232859B/en active IP Right Grant
- 2014-05-28 DO DO2014000115A patent/DOP2014000115A/es unknown
- 2014-06-05 EC ECIEPI20143642A patent/ECSP14003642A/es unknown
- 2014-06-20 CO CO14134660A patent/CO6990728A2/es unknown
- 2014-06-25 MA MA37152A patent/MA35836B1/fr unknown
- 2014-06-27 CR CR20140312A patent/CR20140312A/es unknown
- 2014-06-27 ZA ZA2014/04787A patent/ZA201404787B/en unknown
- 2014-10-15 JP JP2014210716A patent/JP6023146B2/ja active Active
2016
- 2016-02-25 JP JP2016034427A patent/JP6074083B2/ja active Active
- 2016-06-28 US US15/194,984 patent/US9908907B2/en active Active
- 2016-12-09 CY CY20161101278T patent/CY1118416T1/el unknown
- 2016-12-22 SM SM201600467T patent/SMT201600467B/it unknown
2018
- 2018-01-18 US US15/874,325 patent/US10208073B2/en active Active
- 2018-12-21 US US16/228,835 patent/US10717721B2/en active Active
2020
- 2020-06-08 US US16/896,135 patent/US11312698B2/en active Active
- 2020-06-16 LT LTPA2020510C patent/LTC2785706I2/lt unknown
- 2020-06-18 NL NL301047C patent/NL301047I2/nl unknown
- 2020-06-24 FI FIC20200022C patent/FIC20200022I1/fi unknown
- 2020-07-03 FR FR20C1029C patent/FR20C1029I2/fr active Active
- 2020-07-03 CY CY2020017C patent/CY2020017I2/el unknown
- 2020-08-18 HU HUS2000032C patent/HUS2000032I1/hu unknown
2022
- 2022-03-21 US US17/699,522 patent/US12071421B2/en active Active

Also Published As

Publication number	Publication date
TW201331181A (zh)	2013-08-01
EP2785706B1 (en)	2016-09-14
AU2012346133B2 (en)	2016-10-06
JP2015017121A (ja)	2015-01-29
SMT201600467B (it)	2017-03-08
PT2785706T (pt)	2016-12-16
NI201400043A (es)	2015-09-21
CN111662330B (zh)	2023-05-12
UA115136C2 (uk)	2017-09-25
MD4539C1 (ro)	2018-07-31
US10208073B2 (en)	2019-02-19
DK2785706T3 (en)	2016-12-12
FR20C1029I1 (fr)	2020-10-02
US11312698B2 (en)	2022-04-26
US8426450B1 (en)	2013-04-23
CN112979543B (zh)	2024-09-24
SMT201600467T1 (it)	2017-03-08
NL301047I2 (nl)	2023-08-01
EP2785706A1 (en)	2014-10-08
MY165514A (en)	2018-03-28
AR089019A1 (es)	2014-07-23
US9908907B2 (en)	2018-03-06
AU2012346133A1 (en)	2014-04-17
CA2850644C (en)	2020-08-11
IL232859A0 (en)	2014-07-31
FR20C1029I2 (fr)	2023-12-29
CR20140312A (es)	2014-08-27
US8895586B2 (en)	2014-11-25
HUE032288T2 (hu)	2017-09-28
LTC2785706I2 (lt)	2023-07-10
ECSP14003642A (es)	2015-12-31
WO2013082102A1 (en)	2013-06-06
MA35836B1 (fr)	2014-12-01
US12071421B2 (en)	2024-08-27
BR112014012878A2 (pt)	2017-06-13
US20220401463A1 (en)	2022-12-22
TWI638806B (zh)	2018-10-21
CN106986822A (zh)	2017-07-28
US20180194788A1 (en)	2018-07-12
BR112014012878B1 (pt)	2022-05-31
CN112979543A (zh)	2021-06-18
LTPA2020510I1 (lt)	2020-07-10
NL301047I1 (fi)	2020-06-24
NZ623746A (en)	2016-07-29
US20170050993A1 (en)	2017-02-23
SI2785706T1 (sl)	2017-01-31
JP2014507446A (ja)	2014-03-27
UY34472A (es)	2013-06-28
BR112014012878A8 (pt)	2021-06-15
PH12014501199A1 (en)	2014-09-08
CY2020017I1 (el)	2020-11-25
AP2014007729A0 (en)	2014-06-30
MX2014006423A (es)	2014-09-08
PH12014501199B1 (en)	2014-09-08
CA2850644A1 (en)	2013-06-06
CY2020017I2 (el)	2020-11-25
MD20140059A2 (en)	2014-11-30
IL232859B (en)	2018-01-31
LT2785706T (lt)	2016-12-12
CN106986822B (zh)	2020-04-21
SG11201402044XA (en)	2014-09-26
RS55448B1 (sr)	2017-04-28
PE20141421A1 (es)	2014-10-03
CY1118416T1 (el)	2017-06-28
JP6074083B2 (ja)	2017-02-01
CN106518924B (zh)	2019-10-08
DOP2014000115A (es)	2014-07-15
JP5635708B2 (ja)	2014-12-03
US20190177296A1 (en)	2019-06-13
CO6990728A2 (es)	2014-07-10
KR20140103991A (ko)	2014-08-27
MD4539B1 (ro)	2017-12-31
JP6023146B2 (ja)	2016-11-09
GEP201706695B (en)	2017-07-10
US20130231315A1 (en)	2013-09-05
HK1199030A1 (zh)	2015-06-19
PL2785706T3 (pl)	2017-03-31
TN2014000165A1 (en)	2015-09-30
GT201400102A (es)	2015-12-07
US20200399240A1 (en)	2020-12-24
US10717721B2 (en)	2020-07-21
ES2603958T3 (es)	2017-03-02
HUS2000032I1 (hu)	2020-09-28
EA201400624A1 (ru)	2015-01-30
CN106518924A (zh)	2017-03-22
ME02561B (me)	2017-02-20
CN111662330A (zh)	2020-09-15
JO3202B1 (ar)	2018-03-08
KR101979050B1 (ko)	2019-05-15
HRP20161708T1 (hr)	2017-02-10
IN2014CN04907A (fi)	2015-09-18
CN112961104A (zh)	2021-06-15
CL2014001280A1 (es)	2014-11-07
EA026553B1 (ru)	2017-04-28
JP2016147868A (ja)	2016-08-18
CN104053652A (zh)	2014-09-17
ZA201404787B (en)	2015-12-23

Publication	Publication Date	Title
FIC20200022I1 (fi)	2020-06-24	Yhdistelmä, joka käsittää fosnetupitanttia tai sen farmaseuttisesti hyväksyttävää suolaa ja palonosetronia tai sen farmaseuttisesti hyväksyttävää suolaa
FIC20250016I1 (fi)	2025-03-31	Akoramidiisi ja/tai sen farmaseuttisesti hyväksyttävä suola, erityisesti akoramidiisihydrokloridi
FIC20230028I1 (fi)	2023-08-28	Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
FIC20240012I1 (fi)	2024-04-18	Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
NO2021034I1 (no)	2021-09-09	pemigatinib or a pharmaceutically acceptable salt thereof
NO2023023I1 (no)	2023-05-24	Maralixibat, or a pharmaceutically acceptable salt thereof, in particular maralixibat chloride
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NO2023040I1 (no)	2023-10-20	Atogepant or a pharmaceutically acceptable salt thereof
NL301197I2 (nl)	2022-11-04	daridorexant of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder daridorexanthydrochloride
NO2022031I1 (no)	2022-07-20	Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
FIC20240032I1 (fi)	2024-10-01	Iptakopaani tai sen farmaseuttisesti hyväksyttävä suola
FIC20230035I1 (fi)	2023-11-22	Ritlesitinibi tai sen farmaseuttisesti hyväksyttävä suola
FIC20230036I1 (fi)	2023-12-01	Mavakamteeni tai sen farmaseuttisesti hyväksyttävä suola
FIC20240022I1 (fi)	2024-06-19	Retsafungiini tai sen farmaseuttisesti hyväksyttävä suola, erityisesti retsafungiiniasetaatti
NO2025011I1 (no)	2025-02-17	Erdafitinib or a pharmaceutically acceptable salt thereof or a solvate thereof
FIC20240016I1 (fi)	2024-05-31	Dolutegraviiri tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien dolutegraviirinatrium, ja lamivudiini
NO2021033I1 (no)	2021-09-06	Selineksor eller et farmasøytisk akseptabelt salt derav
LUC00083I2 (en)	2018-10-15	Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium
NO2022005I1 (no)	2022-02-03	Zanubrutinib or a pharmaceutically acceptable salt thereof
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NO2022004I1 (no)	2022-02-01	abrocitinib, or a pharmaceutically acceptable salt thereof
FIC20250019I1 (fi)	2025-05-07	Imetelstaatti tai sen farmaseuttisesti hyväksyttävä suola
NO2019019I1 (no)	2019-04-24	Doravirin eller et farmasøytisk akseptabelt salt derav